Compassionate Use of Ibalizumab for the Treatment of HIV Infection
Status:
No longer available
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Ibalizumab is a humanized immunoglobulin G monoclonal antibody directed against a human
T-cell receptor (CD4) and thus suppresses HIV replication by blocking entry of HIV into CD4+
lymphocytes. Ibalizumab has completed phase I and II clinical studies in HIV-negative and
HIV-infected individuals showing safety and efficacy for suppressing HIV replication.